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insured population who underwent mastectomy for breast cancer
then ﬁlled a ﬁrst prescription for an oral adjuvant hormonal
agent (OAHA, deﬁned as tamoxifen or an aromatase inhibitor)
within one year after surgery, and had continuous eligibility for
pharmacy beneﬁts from six months prior to surgery. Patients
were excluded if they had claims coded for distant metastasis or
chemotherapy agents speciﬁc for advanced cancer. Days covered
by OAHA are deduced from dispensed dates and days supplied.
Time to nonpersistence (deﬁned as 180 days without OAHA
coverage) is estimated using a Kaplan-Meier analysis and the
relation assessed between time to nonpersistence and age and
history of cytotoxic adjuvant chemotherapy or radiation therapy
preceding endocrine therapy. RESULTS: A total fo 3654 women
(age mean 59.8, SD 12.4) were identiﬁed who satisﬁed study
criteria, underwent mastectomy between July1998 and Decem-
ber 2006, and had pharmacy beneﬁts eligibility extending
through 2007 or at least 180 days after deduced exhaustion of
last OAHA supply. A total of 33.2% had claims consistent with
cytotoxic adjuvant chemotherapy and 65% had claims for radia-
tion therapy. Including as right-censored patients still receiving
therapy at study end (n = 1516) and those lost to follow-up
(n = 969), the cumulative nonpersistence rate is estimated as
24% at three years. Nonpersistence rates were higher for the
youngest and oldest patients, and lower for patients with a
preceding history of cytotoxic chemotherapy or radiation
therapy. CONCLUSION: It is important to increase understand-
ing of the determinants of persistence with cancer therapies
administered orally for long time periods.
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OBJECTIVE: The prevalence of prostate cancer increases with
age. Leuprolide acetate is an efﬁcacious therapy in patients with
prostate cancer. Therapy persistence is essential for desirable
clinical outcomes. METHODS: A retrospective analysis was con-
ducted using the Medstat MarketScan database on a commer-
cially and Medicare aged insured population from 2001–2005.
The MarketScan database collects medical claims, pharmacy
claims, cost, and demographics data. Subjects new to leuprolide
acetate (identiﬁed by J-Code of J9217) in 2002 and no codes in
2001 were followed for 3 years. Compliance was calculated
using the medication possession ratio (MPR = total days supply
obtained/days on therapy). Persistence was characterized by the
number of ﬁlls and the days on therapy (start plus estimated
discontinuation date). Subjects were stratiﬁed into age-range
groups, by those >18 and <51 yr, those >81 yr, and 10-year age
ranges in between (51–60, 61–70, 71–80). Survival rate was
calculated using Kaplan–Meier survival curves. RESULTS: A
total of 1541 men with prostate cancer receiving leuprolide
acetate were included in the study. The average MPR for all ages
was 0.70 (Standard Deviation [SD] = 0.15) and did not change
signiﬁcantly by age. Average months persistence was 15.9
months (SD = 11.8, N = 1541) and generally increased with age
from 10.6 months (SD = 12.4, N = 59) for those 18–50 years;
14.8 months (SD = 13.5, N = 188) for those 51–60 years; 12.5
months (SD = 11.2, n = 302) for those 61–70 years; 16.7 months
(SD = 11.4, N = 718) for those 71–80 years; and 19.8 months
(SD = 10.4, N = 274) for those over 80 years. More than one-
third of patients discontinued by six months of therapy.
CONCLUSION: Leuprolide acetate therapy persistence in-
creased with age. Persistency improvement efforts in younger
patients and during the ﬁrst six months of therapy may result in
better outcomes.
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OBJECTIVE: To examine differences in medication adherence to
adjuvant hormonal therapy between white and black patients
with breast cancer using different statistical techniques. The data
source: Linked North Carolina Medicaid claims-Tumor Registry
data (years 1999–2005). METHODS: The study design was a
retrospective cohort study of Medicaid enrollees with breast
cancer newly starting adjuvant hormonal therapy (tamoxifen or
aromatase inhibitor) between years January 2000 to December
2004. Medication adherence [measured as Medication Posses-
sion Ratio (MPR)] was assessed using patients’ prescription reﬁll
records. The Medicaid claims and CCR data were merged using
a probabilistic match algorithm. From the linked data, informa-
tion on patients with ICD-9 codes for primary breast cancer was
extracted. RESULTS: Black patients had a 7% and 9% lower
adherence rate as compared to white patients in the propensity
score and regression method respectively. Stratiﬁcation based on
80% cut-off point for the MPR showed that black patients were
21% less likely to be in the high adherence group. CONCLU-
SION: Results from the propensity score and regression analysis
may agree so closely in this study because there was good overlap
in the distribution of background characteristics for the white
and black women with primary breast cancer enrolled in
Medicaid.
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OBJECTIVE: To determine predictors of quality of life (QoL)
in community-dwelling prostate cancer (PC) survivors.
METHODS: We derived a population-based sample of PC
patients diagnosed in 1993–4, 1997–8 and 2001–2, residing in
3 geographically diverse areas of Ontario, from the Ontario
Cancer Registry (n = 2749, survivors = 1961). Consenting survi-
vors (n = 851) were mailed questionnaires, including the Health
Utilities Index (HUI 2/3), Patient-Oriented Prostate Utility
Scale [PORPUS-P (psychometric) and PORPUS-Ui (utility)],
Functional Assessment of Cancer Therapy-Prostate (FACT-P),
Prostate Cancer Index (PCI), and a consent form for chart review.
We constructed univariate and multivariate regression models to
determine the effects of patient-, disease-, system-, and symptom-
related variables on QoL. RESULTS: A total of 670 patients
returned completed questionnaires and 620 charts were reviewed
(others lost, destroyed; 597 entered for these analyses). Mean
(SD) PORPUS-P score was 71.78 (14.00), mean PORPUS-Ui
was 0.86 (0.11), mean HUI3 was 0.78 (0.24), and mean FACT-P
was 127.26 (18.40). In univariate analyses with patient-related
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